Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia

Early Intervention in Psychiatry

Volumn 4, Issue 1, 2010, Pages 64-78

  Canuso, Carla M ^a   Bossie, Cynthia A ^a   Amatniek, Joan ^a   Turkoz, Ibrahim ^a   Pandina, Gahan ^b   Cornblatt, Barbara ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Paliperidone ER; Schizophrenia; Treatment outcome

Indexed keywords

PALIPERIDONE; PLACEBO;

AKATHISIA; AMENORRHEA; ANORGASMIA; ANXIETY; ARTICLE; BREAST DISCHARGE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DEPRESSION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; LIBIDO DISORDER; MENSTRUAL IRREGULARITY; MUSCLE HYPERTONIA; NAUSEA; OLIGOMENORRHEA; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; SOMNOLENCE; TACHYCARDIA; WEIGHT GAIN;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOXAZOLES; MALE; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 75649138023     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2010.00165.x     Document Type: Article

References (44)

1. Keshavan MS, Schooler NR. First-episode studies in schizophrenia: criteria and characterization. Schizophr Bull 1992, 18:491-513.
2. Lieberman JA, Perkins D, Belger A. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001, 50:884-97.
3. Rosen K, Garety P. Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes. Schizophr Bull 2005, 31:735-50.
4. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999, 46:729-39.
5. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 2008, 7:148-56.
6. Malla AK, Norman RM, Joober R. First-episode psychosis, early intervention, and outcome: what have we learned? Can J Psychiatry 2005, 50:881-91.
7. Chakos MH, Schobel SA, Gu H. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br J Psychiatry 2005, 186:26-31.
8. Davidson L, McGlashan TH. The varied outcomes of schizophrenia. Can J Psychiatry 1997, 42:34-43.
9. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996, 22:305-26.
10. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002, 57:209-19.
11. McEvoy JP, Lieberman JA, Perkins DO. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164:1050-60.
12. Novak-Grubic V, Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur Psychiatry 2002, 17:148-54.
13. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006, 22:1879-92.
14. Meltzer HY, Bobo WV, Nuamah IF. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008, 69:817-29.
15. Marder SR, Kramer M, Ford L, Eerdekens E, Eerdekens M, Lim P. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007, 62:1363-70.
16. Kane J, Canas F, Kramer M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007, 90:147-61.
17. Kramer M, Simpson G, Maciulis V. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007, 27:6-14.
18. Davidson M, Emsley R, Kramer M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007, 93:117-30.
19. Emsley R, Berwaerts J, Eerdekens M. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008, 23:343-56.
20. International conference on harmonization, good clinical practice: consolidated guidelines. Fed Regist 1997, 62:25691-709. U.S. Department of Health and Human Services. Food and Drug Administration
21. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-76.
22. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997, 58:538-46.
23. Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology 1976, 218-22. In, National Institute of Mental Health, ed., Revised, 1976 ed., Rockville, MD, U.S. Department of Health and Human Services
24. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101:323-29.
25. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
26. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-76.
27. Guy WA. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology 1972, 534-37. In, National Institute of Mental Health, ed., Washington, DC, U.S. Department of Health, Education and Welfare
28. Hedges LV, Olkin I. Statistical Methods for Meta-analysis 1985, New York, Academic Press
29. Lieberman J, Jody D, Geisler S. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993, 50:369-76.
30. Schooler N, Rabinowitz J, Davidson M. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005, 162:947-53.
31. Cahn W, Hulshoff Pol HE, Lems EB. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry 2002, 59:1002-10.
32. Arvanitis LA, Miller BG. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997, 42:233-46.
33. Keck P, Buffenstein A, Ferguson J. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998, 140:173-84.
34. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999, 20:491-505.
35. McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007, 41:895-905.
36. Lieberman JA, Stroup TS, McEvoy JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-23.
37. Patrick DL, Burns T, Morosini P. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 2009, 25:325-38.
38. Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res 2008, 161:213-24.
39. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, Hernandez J, Gomez-Beneyto M, Schooler NR. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994, 151:1819-21.
40. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 1998, 43:596-604.
41. Parellada E, Andrezina R, Milanova V. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005, 19:5-14.
42. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull 1996, 22:241-56.
43. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996, 22:201-22.
44. Hafner H, Riecher A, Maurer K, Loffler W, Munk-Jorgensen P, Stromgren E. How does gender influence age at first hospitalization for schizophrenia? A transnational case register study. Psychol Med 1989, 19:903-18.